Neurology
Partner With Us
Advertisement

Neuromuscular Disorders

thumb description

December 04, 2025

FDA Approves Biologic for Nerve Repair

A newly licensed biologic offers a novel approach to repairing complex peripheral nerve injuries across pediatric and adult populations.

Conexiant

thumb description

November 25, 2025

FDA OKs First SMA Gene Replacement Therapy

The FDA approved Itvisma, the first gene replacement therapy for children 2 years and older, teens, and adults with spinal muscular atrophy, a one-time treatment that replaces the SMN1 gene and demonstrated improved motor function in Phase 3 studies.

Conexiant

thumb description

November 25, 2025

Brain Shifts at Hidden Ages 

Manifold analysis reveals distinct organizational epochs separated by turning points at ages 9, 32, 66, and 83 years across 4,216 diffusion imaging scans.

Conexiant

thumb description

November 25, 2025

Brain Stimulation Boosts Vision Recovery

Cross-frequency tACS combined with visual training significantly improved motion discrimination and expanded visual fields in chronic hemianopia patients.

Conexiant

Daily News

Stay up to date with the latest clinical headlines and other information tailored to your specialty.

thumb description

November 21, 2025

EULAR: Issues With the RA Definition?

Researchers examine the strengths and shortcomings of the current European Alliance of Associations for Rheumatology definition for difficult-to-treat rheumatoid arthritis.

Conexiant

thumb description

November 21, 2025

Which Antidepressants Shift Physiology?

Researchers found differences in how antidepressants affect weight, blood pressure, heart rate, and other physiological parameters.

Conexiant

thumb description

November 20, 2025

Vorasidenib in IDH1/2-Mutant Low-Grade Glioma

As reported in The Lancet Oncology by Cloughesy et al, vorasidenib was associated with improvement in some secondary and exploratory outcomes vs placebo in the phase III INDIGO trial in patients with ...

The ASCO Post